| Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect C Zhang, M Lin, R Wu, X Wang, B Yang, AJ Levine, W Hu, Z Feng Proceedings of the National Academy of Sciences 108 (39), 16259-16264, 2011 | 452 | 2011 |
| Chronic restraint stress attenuates p53 function and promotes tumorigenesis Z Feng, L Liu, C Zhang, T Zheng, J Wang, M Lin, Y Zhao, X Wang, ... Proceedings of the National Academy of Sciences 109 (18), 7013-7018, 2012 | 212 | 2012 |
| Targeting mTOR network in colorectal cancer therapy XW Wang, YJ Zhang World journal of gastroenterology: WJG 20 (15), 4178, 2014 | 133 | 2014 |
| Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis T Zheng, J Wang, Y Zhao, C Zhang, M Lin, X Wang, H Yu, L Liu, Z Feng, ... Nature communications 4 (1), 2996, 2013 | 121 | 2013 |
| SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer X Wang, H Zhang, R Sapio, J Yang, J Wong, X Zhang, JY Guo, S Pine, ... Nature communications 12 (1), 2259, 2021 | 58 | 2021 |
| Amino acids-Rab1A-mTORC1 signaling controls whole-body glucose homeostasis X Zhang, X Wang, Z Yuan, SJ Radford, C Liu, SK Libutti, XFS Zheng Cell Reports 34 (11), 2021 | 30 | 2021 |
| PP2AC level determines differential programming of p38-TSC-mTOR signaling and therapeutic response to p38-targeted therapy in colorectal cancer Y Zhang, X Wang, X Qin, X Wang, F Liu, E White, XFS Zheng EBioMedicine 2 (12), 1944-1956, 2015 | 27 | 2015 |
| Identification of a non-gatekeeper hot spot for drug-resistant mutations in mTOR kinase TJ Wu, X Wang, Y Zhang, L Meng, JE Kerrigan, SK Burley, XFS Zheng Cell reports 11 (3), 446-459, 2015 | 27 | 2015 |
| Metabolism of ebracteolata compound B studied in vitro with human liver microsomes, HepG2 cells, and recombinant human enzymes X Zhang, Y Yao, Y Lou, H Jiang, X Wang, X Chai, S Zeng Drug metabolism and disposition 38 (12), 2157-2165, 2010 | 24 | 2010 |
| Gankyrin activates mTORC1 signaling by accelerating TSC2 degradation in colorectal cancer X Qin, X Wang, F Liu, LE Morris, X Wang, B Jiang, Y Zhang Cancer letters 376 (1), 83-94, 2016 | 22 | 2016 |
| Stereoselective metabolic and pharmacokinetic analysis of the chiral active components from herbal medicines X Wang, S Zeng Current Pharmaceutical Analysis 6 (1), 39-52, 2010 | 9 | 2010 |
| SOD1 is required for tumor maintenance in a genetically engineered KRAS/TP53 non-small cell lung cancer mouse model X Wang, J Wong, HV Remmen, JY Guo, E White, XFS Zheng Cancer Research 78 (13_Supplement), 2421-2421, 2018 | | 2018 |
